ArticleFrontiers in oncology2026

Double-dose furmonertinib for patients with osimertinib-resistant advanced NSCLC: therapeutic efficacy and safety.

Yepei Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.